Search - tctmd.com

Displaying 21 - 40 of 81

Sort: Relevancy | Date

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

May 16, 2021

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

November 11, 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

October 18, 2020

DISRUPT CAD III: Lithotripsy Boosts Stent Expansion in Highly Calcified Lesions

News Conference News TCT 2020

DISRUPT CAD III: Lithotripsy Boosts Stent Expansion in Highly Calcified Lesions

October 15, 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

News Conference News ACC 2020

Anatomic Burden, Ischemia Severity, and Outcomes in ISCHEMIA

March 29, 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

March 28, 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

News Conference News LINC 2020

Common-Femoral Lesions: LINC 2020 Experts Hash Out the Best PAD Treatment

January 31, 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

January 29, 2020

Leaving the Hospital Nest? OBL Advice From Those Who’ve Done It

News Conference News ISET 2020

Leaving the Hospital Nest? OBL Advice From Those Who’ve Done It

January 28, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

January 24, 2020

PAD Care on the Backdrop of Cancer Requires Creativity, Persistence

News Conference News ISET 2020

PAD Care on the Backdrop of Cancer Requires Creativity, Persistence

January 23, 2020

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

November 16, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

November 06, 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

November 05, 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

September 28, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.